Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(4):310-314; doi:10.1093/jnci/dji053
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (40)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Liotta, L. A.
Right arrow Articles by Petricoin, E. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liotta, L. A.
Right arrow Articles by Petricoin, E. F., III
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

COMMENTARY

Importance of Communication Between Producers and Consumers of Publicly Available Experimental Data

Lance A. Liotta, Mark Lowenthal, Arpita Mehta, Thomas P. Conrads, Timothy D. Veenstra, David A. Fishman, Emanuel F. Petricoin, III

Affiliations of authors: FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, National Cancer Institute, CCR, Bethesda, MD (LAL, AM, ML); National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD (TPC, TDV); National Ovarian Cancer Early Detection Program, New York University, New York, NY (DAF); FDA-NCI Clinical Proteomics Program, Office of Cell Therapy and Gene Therapy, CBER, Food and Drug Administration, Bethesda, MD (EFP)

Correspondence to: Emanuel F. Petricoin III, PhD, FDA-NCI Clinical Proteomics Program, Office of Cell Therapy and Gene Therapy, CBER, Food and Drug Administration, Bethesda, MD 20892 (e-mail: petricoin{at}cber.fda.gov).

The application of mass spectrometry to discover new cancer biomarkers is in its infancy. Many of these new markers are low-abundance proteins that exist as fragments associated with carrier proteins. Although reproducibility is key to the use of mass spectrometry for ion fingerprint analysis, the scientific community has yet to establish a common platform or standardized operating procedures that are necessary for intra- and inter-laboratory comparison. In an effort to assist others who are perfecting mass spectrometry platforms for profiling, ongoing experimental data were posted for public consumption. An unintended consequence of unrestricted access to experimental data is the risk of inappropriate conclusions drawn and publicly disseminated that could have been avoided by communication between the producers and consumers of the data. Such disputes, however, should not divert us from the validation of this promising new approach.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Lessons from Controversy: Ovarian Cancer Screening and Serum Proteomics
David F. Ransohoff
J Natl Cancer Inst 2005 97: 315-319. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Clin. Chem.Home page
M. F. Lopez, A. Mikulskis, S. Kuzdzal, E. Golenko, E. F. Petricoin III, L. A. Liotta, W. F. Patton, G. R. Whiteley, K. Rosenblatt, P. Gurnani, et al.
A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples
Clin. Chem., June 1, 2007; 53(6): 1067 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. G. Marguiles, V. S. Klimberg, S. Bhattacharrya, D. Gaddy, and L. J. Suva
Genomics and Proteomics of Bone Cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6217s - 6221s.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. P. Diamandis
Serum Proteomic Profiling by Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry for Cancer Diagnosis: Next Steps
Cancer Res., June 1, 2006; 66(11): 5540 - 5541.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Karsan, B. J. Eigl, S. Flibotte, K. Gelmon, P. Switzer, P. Hassell, D. Harrison, J. Law, M. Hayes, M. Stillwell, et al.
Analytical and Preanalytical Biases in Serum Proteomic Pattern Analysis for Breast Cancer Diagnosis
Clin. Chem., August 1, 2005; 51(8): 1525 - 1528.
[Full Text] [PDF]

Home page
 JCOHome page
M. Goggins
Molecular Markers of Early Pancreatic Cancer
J. Clin. Oncol., July 10, 2005; 23(20): 4524 - 4531.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.